Trials / Approved For Marketing
Approved For MarketingNCT04428632
Oral Berotralstat Expanded Access Program
Expanded Access Program With Oral Berotralstat for the Prevention of Attacks in Patients With Hereditary Angioedema
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- BioCryst Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.
Detailed description
Physicians may request access to berotralstat for eligible participants with unmet medical need Physicians can send email inquiries to access.us@inceptua.com or call 1-888-225-8677 Patients who may be interested should contact their physician about participation Berotralstat (BCX7353) will be available through this expanded access program until it is commercially available
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Berotralstat | One 150mg capsule administered orally once daily |
Timeline
- First posted
- 2020-06-11
- Last updated
- 2020-12-11
Source: ClinicalTrials.gov record NCT04428632. Inclusion in this directory is not an endorsement.